CB8025-21730 NASH

This is a phase 2, double-blind, randomized, placebo-controlled study to evaluate the activity of seladelpar in subjects with Non-alcoholic Steatohepatitis (NASH).

The primary objective is to evaluate the effect of seladelpar on hepatic fat fraction, assessed by MRI-PDFF at week 12 and to evaluate the safety and tolerability of seladelpar in subjects with NASH.

Learn More

Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.


Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.

Get In Touch

We’d love to hear from you!

Excel Medical Clinical Trials LLC
7900 Glades Road, Suite 400
Boca Raton, FL 33434